HIMS & HERS HEALTH, INC. (HIMS) — Fundamental Analysis

Hims & Hers Health (HIMS) is a telehealth and wellness company that has grown at a blistering pace — nearly tripling revenue over just three years — and only recently crossed into sustained profitability at the annual level. The headline story is genuinely impressive top-line momentum, but the most recent quarterly filing throws cold water on that narrative: gross margins have compressed sharply, the business swung back to an operating loss, and the current ratio dipped below 1.0 for the first time in the company's public history. Capital spending has also surged, signaling heavy reinvestment. In short, HIMS is a high-growth company still in transition — it has proven it can scale revenue, but it has not yet proven it can hold onto the profitability it briefly achieved in 2024 and 2025.

Snapshot & Big Picture

Founded as a direct-to-consumer telehealth platform offering personalized treatments for hair loss, sexual health, mental wellness, and weight management, Hims & Hers has transformed from a small-scale startup into a business approaching $2.4 billion in annual revenue. Revenue grew from $82.6 million in fiscal 2019 to $2.35 billion in fiscal 2025 — a roughly 28x increase in six years. The company burned cash heavily through 2022, trimmed losses in 2023, and achieved positive net income for the first time in 2024 before expanding that profit in the 2025 annual figures. However, the most recent quarterly data (Q2 2026, ended June 30, 2026) signals meaningful near-term pressure, with the company posting a net loss and a current ratio that has slipped below 1.0.

Latest Quarter Snapshot (Q2 2026 — Most Current Data)

The most recent filing covers the quarter ended June 30, 2026, and represents a material shift from the annual trends. Revenue for the quarter came in at $753.2 million, which annualizes to roughly $3 billion — so top-line growth is continuing. However, profitability has deteriorated sharply. Gross margin fell to 63.8%, down from 73.8% for full-year 2025 and the 82.0% peak in 2023, suggesting meaningful cost pressure or a shift in product/service mix. The operating margin dropped to -12.9% and net margin to -11.5%, a significant reversal from the profitable 2024 and 2025 annual periods.

Perhaps most notably, the current ratio fell to 0.93 — meaning current liabilities now exceed current assets. This is the first time in the company's reported history that this ratio has gone below 1.0, a flag worth monitoring closely for short-term liquidity. Capital expenditures for the quarter were $32.3 million (4.3% of revenue), consistent with the elevated investment pace seen in 2025.

Profitability

The multi-year profitability arc is one of the more dramatic turnarounds in recent consumer health history. In 2019, the company lost nearly 90 cents on every dollar of revenue at the operating level. By 2020, a combination of rapid revenue scaling and gross margin expansion (from 54% to 73.6%) cut those losses sharply. The business continued to bleed through 2021 and 2022 as it invested heavily in marketing and infrastructure, before narrowing losses significantly in 2023. Fiscal 2024 was the inflection year — both operating and net margins turned positive for the first time, and 2025 held those gains with EBITDA of $160.1 million.

The Q2 2026 quarterly results, however, represent a meaningful reversal. Gross margin compression of roughly 10 percentage points compared to full-year 2025 is the most concerning signal — if sustained, it would eliminate the thin operating profit the company worked years to achieve. Whether this is a temporary disruption (mix shift, one-time costs, regulatory changes around compounded GLP-1 medications) or a structural change in the business model is the central question for investors right now.

Financial Health

Hims & Hers has historically carried no long-term debt in its reported filings — the debt-to-equity ratio was not available (null) across all periods in the data, which is consistent with a balance sheet that has relied primarily on equity financing. The current ratio has generally been comfortable, ranging from a high of 7.4x in 2020 down to 1.9x by end of 2025 as the business deployed more cash. The dip to 0.93x in Q2 2026 is a notable development that warrants close attention in upcoming filings.

Capital Expenditures: Capital intensity has increased substantially and is an important part of the HIMS story. In the early years (2019–2021), capex figures were not reported in the available filings. Starting from 2022, capex was modest at $7.2 million (1.4% of revenue). It stepped up to $26.5 million in 2023 (3.0% of revenue), then to $52.8 million in 2024 (3.6% of revenue), before surging to $242.6 million in 2025 — representing 10.3% of revenue. This sharp increase suggests the company is making significant investments in physical infrastructure, likely pharmacy fulfillment or manufacturing capacity related to its compounded medication offerings. At 4.3% of revenue in Q2 2026, the quarterly pace has moderated somewhat from the 2025 annual peak, but the absolute level remains elevated relative to the company's early history.

Growth

The revenue CAGR figures below confirm that HIMS has been one of the fastest-growing companies in the consumer health space over the measured periods. A 10-year CAGR is not available because the company's SEC filing history does not extend back a full decade. The 3-year and 5-year figures are both exceptional by any standard, though it is worth noting that high-percentage growth from a small base becomes progressively harder to sustain as the denominator grows.

A 3-year revenue CAGR of 64.5% and a 5-year CAGR of 73.6% are extraordinary figures, reflecting the explosive growth of HIMS's telehealth and compounded medication businesses. Even if growth decelerates substantially from here — as the Q2 2026 quarterly revenue run-rate suggests it still may be growing — the base of operations has scaled to a point where sustaining high double-digit growth becomes progressively more difficult and where margin discipline matters more than ever.

Source Filings

• 10-Q filed August 10, 2026 — Period ended June 30, 2026
• 10-Q filed May 11, 2026 — Period ended March 31, 2026